Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Journal of the American Heart Association|March 10, 2020
Rates of Potentially Inappropriate Dosing of Direct-Acting Oral Anticoagulants and Associations With Geriatric Conditions Among Older Patients With Atrial Fibrillation: The SAGE-AF StudySaket Sanghai, Cecillia Wong, Ziyue Wang, et al.
Journal of Primary Care & Community Health|July 30, 2024
Screening for Autism Spectrum Disorder in Young Children: Still Not Enough EvidenceBogdan Grigore, Jaime Peters, Jessica Williams, et al.
Science Translational Medicine|June 12, 2010
Gatekeeper mutations mediate resistance to BRAF-targeted therapiesSteven Whittaker, Ruth Kirk, Robert Hayward, et al.
BMC Public Health|August 23, 2002
Comparison of deferral rates using a computerized versus written blood donor questionnaire: a randomized, cross-over study [ISRCTN84429599]John W Sellors, Robert Hayward, Graham Swanson, et al.
BMC Cardiovascular Disorders|July 1, 2021
Contemporary procedure characteristics and outcomes of accessory atrioventricular pathway ablations in an integrated community-based health care system using a tiered approachCharlie Young, Annie Kwan, Lisa Yepez, et al.
Chemical Communications (Cambridge, England)|October 10, 2018
Essential but sparse collagen hydroxylysyl post-translational modifications detected by DNP NMRWing Ying Chow, Rui Li, Ieva Goldberga, et al.
Public Health in Practice (Oxford, England)|October 15, 2024
Mapping vulnerability to climate-related hazards to inform local authority action in adaptation: A feasibility studyJ Howkins, Daniela N Schmidt, James Thomas, et al.
Pigment Cell & Melanoma Research|December 17, 2009
Inducible expression of (V600E) Braf using tyrosinase-driven Cre recombinase results in embryonic lethalityNathalie Dhomen, Silvy Da Rocha Dias, Robert Hayward, et al.
Oncogene|June 23, 2004
B-RAF is a therapeutic target in melanomaMaria Karasarides, Antonio Chiloeches, Robert Hayward, et al.
Cancer Cell|December 16, 2011
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemiaLeisl M Packer, Sareena Rana, Robert Hayward, et al.
Pageof 5